AbbVie (ABBV)
(Delayed Data from NYSE)
$188.86 USD
+0.29 (0.15%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $188.60 -0.26 (-0.14%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
Price, Consensus and EPS Surprise
ABBV 188.86 +0.29(0.15%)
Will ABBV be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for ABBV based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ABBV
Pharma Stock Roundup: JNJ's Q3 Earnings, FDA Nod to Some New Drugs
The Zacks Analyst Blog Highlights AbbVie, Automatic Data Processing, Analog Devices, Taylor Devices and Village Super Market
ABBV: What are Zacks experts saying now?
Zacks Private Portfolio Services
AbbVie Secures FDA Approval for Parkinson's Disease Drug Vyalev
AbbVie (ABBV) Falls More Steeply Than Broader Market: What Investors Need to Know
Top Stock Reports for AbbVie, ADP & Analog Devices
Other News for ABBV
Analysts Offer Insights on Healthcare Companies: Merit Medical Systems (MMSI), AbbVie (ABBV) and Elevance Health (ELV)
AbbVie price target raised by $10 at BofA, here's why
Allergan's BOTOX Cosmetic gets FDA approval in jaw-neck bands
FDA Approves AbbVie's VYALEV as First 24-Hour Levodopa Infusion for Advanced Parkinson's
FDA Approves AbbVie's Parkinson's Treatment, Medicare Coverage Expected Next Year